|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.020 USD | +4.16% |
|
-0.66% | -14.10% |
| 07-16 | Moderna advances its cancer therapy assessment, but the stock slides |  |
| 06-01 | Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies | CI |
| Market Cap | 1.18B 1.03B 959M 881M 1.66B 113B 1.69B 11.3B 4.43B 56.25B 4.44B 4.35B 186B | P/E 2026 * |
-4.43x | P/E 2027 * | -4.78x |
|---|---|---|---|---|---|
| Enterprise Value | 1B 870M 811M 746M 1.41B 95.44B 1.43B 9.56B 3.75B 47.58B 3.76B 3.68B 158B | EV / Sales 2026 * |
21x | EV / Sales 2027 * | 18.4x |
| Free-Float |
74.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +4.16% | ||
| 1 week | -0.66% | ||
| Current month | +4.16% | ||
| 1 month | -9.35% | ||
| 3 months | -16.40% | ||
| 6 months | -9.71% | ||
| Current year | -14.10% |
| 1 week | 8.17 |  | 9.57 |
| 1 month | 8.17 | | 10.89 |
| Current year | 8.17 | | 11.94 |
| 1 year | 5.05 | | 12.41 |
| 3 years | 3.3 | | 13.77 |
| 5 years | 3.3 | | 16.3 |
| 10 years | 0 | | 18.42 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 2018-12-31 | |
Venkat Ramanan
DFI | Director of Finance/CFO | 57 | 2025-09-30 |
Liane Preussner
CTO | Chief Tech/Sci/R&D Officer | - | 2024-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 2020-06-30 | |
Peter Chambré
CHM | Chairman | 70 | 2012-09-30 |
Michael Atieh
BRD | Director/Board Member | 72 | 2020-06-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 3/17/26 | Other | Director | 436,021 | 0.3252% | ||
| 6/9/20 | Arya Sciences Holdings
| Others | Company | 499,000 | 3.4713% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | -0.66% | +39.20% | -28.47% | 1.18B | |
| +0.05% | +2.80% | +38.17% | +74.12% | 56.54B | |
| -3.06% | -10.22% | +23.62% | +58.59% | 53.6B | |
| +1.84% | +3.27% | -14.06% | -12.13% | 22.91B | |
| -0.15% | -7.92% | -9.42% | +352.23% | 21.37B | |
| +0.15% | -0.77% | +23.76% | -11.52% | 20.27B | |
| -0.67% | -1.73% | +33.09% | -31.09% | 17.56B | |
| -1.45% | -7.24% | +17.67% | +563.14% | 14.75B | |
| +9.91% | +2.64% | +188.84% | +326.19% | 13.53B | |
| +3.83% | -0.56% | +47.77% | +170.70% | 13.33B | |
| Average | +1.46% | -2.16% | +38.87% | +146.18% | 23.5B | |
| Weighted average by Cap. | +0.16% | -1.72% | +31.75% | +122.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.66M 41.42M 38.63M 35.5M 66.94M 4.54B 68.12M 455M 178M 2.27B 179M 175M 7.5B | 52.53M 45.65M 42.57M 39.12M 73.78M 5.01B 75.07M 502M 197M 2.5B 197M 193M 8.27B |
| Net income | -277M -241M -224M -206M -389M -26.4B -396M -2.64B -1.04B -13.16B -1.04B -1.02B -43.59B | -277M -241M -224M -206M -389M -26.4B -396M -2.65B -1.04B -13.16B -1.04B -1.02B -43.59B |
| Net Debt | -182M -159M -148M -136M -256M -17.39B -261M -1.74B -683M -8.67B -685M -670M -28.71B | -219M -191M -178M -163M -308M -20.91B -314M -2.1B -821M -10.43B -824M -806M -34.53B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-03 | US$9.020 | +4.16% | 257,447 |
| 26-07-31 | US$8.660 | -5.87% | 213,102 |
| 26-07-30 | US$9.200 | +2.34% | 1,607,996 |
| 26-07-29 | US$8.990 | +2.92% | 433,924 |
| 26-07-28 | US$8.735 | +1.22% | 535,040 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMTX Stock
Select your edition
All financial news and data tailored to specific country editions
